

I. Claims 1-4, drawn to isolated polypeptides of one or both of SEQ ID NOS:2 and 4, classified in class 530, subclass 350.

II. Claims 5-8, 22-23 drawn to isolated polynucleotides, vectors, and host cells . classified in class 536, subclass 23.5; class 435, subclasses 325, 320.1.

III. Claims 9, 35 drawn to antibodies, classified in class 530, subclasses 387.1, 388.1.

IV. Claims 10-15, 17-18, drawn to a method of treating tumors comprising modulating the activity of hSTRA6, wherein said modulation comprises decreasing the expression of hSTRA6 via anti-sense or an aptamer, classified in class 424, subclass 93.2.

V. Claims 10-12, 16-18, as specifically drawn to a method of treating tumors comprising decreasing the activity of hSTRA6, wherein said decreasing comprises administering to a cell an antibody, classified in class 424, subclass 130.1.

VI. Claims 19-20, drawn to a method for determining whether a compound up-regulates or down-regulates transcription of a hSTRA6 gene comprising contacting said compound with a composition comprising an RNA polymerase, classified in class 435, subclass 6.

VII. Claim 21, drawn to a method for determining whether a compound up-regulates or down-regulates the translation of an hSTRA6 gene comprising contacting said compound with a composition with a cell, classified in class 435, subclasses 4, 7.1

VIII. Claims 24-26, 34 drawn to a method of screening a tissue sample for tumorigenic potential comprising measuring expression of hSTRA6, classified in class 435, subclass 40.52.

IX. Claims 27-31, drawn to a transgenic non-human animal, classified in class 800, subclass 2.

X. Claim 33, drawn to a method of screening a sample for a hSTRA6 gene mutation,